Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Non-Current Assets (2022 - 2025)

TriSalus Life Sciences' Non-Current Assets history spans 4 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 6.51% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $13.0 million, down 19.65%, while the annual FY2025 figure was $3.1 million, 6.51% down from the prior year.
  • Non-Current Assets reached $3.1 million in Q4 2025 per TLSIW's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $251.0 million in Q3 2022 to a low of $3.1 million in Q4 2025.
  • Average Non-Current Assets over 4 years is $51.6 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: crashed 98.2% in 2023, then decreased 6.51% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $4.8 million in 2022, then decreased by 21.86% to $3.7 million in 2023, then dropped by 11.62% to $3.3 million in 2024, then decreased by 6.51% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Non-Current Assets are $3.1 million (Q4 2025), $3.1 million (Q3 2025), and $3.2 million (Q2 2025).